Should the use of a brachytherapy boost affect the duration or use of ADT in intermediate or high risk prostate cancer?  

Does the 1 year of ADT used in the ASCENDE-RT trial present a new option of the standard of care in timing ADT when combined with brachtherapy boost?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at CoxHealth Radiation Oncology
Thank you for posting this important question and ...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at St. James Cancer Center
How do the NCCN guideline panel members justify th...
Sign in or Register to read more